CardiaLen
company
About
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
- 11 - 50
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $2.80M
- Industries
- Biotechnology,Life Science,Medical Device
- Founded date
- Jan 1, 2008
- Number Of Employee
- 11 - 50
- Operating Status
- Active
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation. The company is developing implantable low-energy (low voltage) pain-free atrial cardioverters to help address the major unmet needs of this condition.
It was founded in 2008 and headquartered in Minneapolis, Minnesota.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$4.32M
CardiaLen has raised a total of
$4.32M
in funding over 2 rounds. Their latest funding was raised on
Jan 19, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 19, 2021 | Grant | $2.80M | 1 |
National Institutes of Health
|
— | Detail |
| Mar 26, 2015 | Series B | $1.52M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
CardiaLen is funded by 2 investors.
National Institutes of Health
and Twin Cities Angels
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
Twin Cities Angels
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
